Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 2/20 | 0.39 |
| ▸ | NAMPT | P43490 | 11/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.34 |
| ▸ | KIT | P10721 | 1/20 | 0.33 |
| ▸ | AURKA | O14965 | 1/20 | 0.32 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.32 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22015587 | 0.88 | KIT (0.43) | NLRP3ACHENAMPTKITALDH1A1 | |
| SCHEMBL29838853 | 0.81 | NLRP3 (0.41) | NLRP3NAMPT | |
| SCHEMBL21963145 | 0.74 | ACHE (0.35) | NLRP3ACHENAMPTCYP2C9CYP2C19 | |
| SCHEMBL24979079 | 0.74 | ACHE (0.35) | NLRP3ACHENAMPTCYP2C9CYP2C19 | |
| SCHEMBL18007714 | 0.73 | NLRP3 (0.44) | NLRP3ACHENAMPTCYP2C9CYP2C19 | |
| SCHEMBL18029805 | 0.73 | ACHE (0.42) | NLRP3ACHENAMPTCYP2C9CYP2C19 | |
| SCHEMBL22021176 | 0.73 | ADORA2A (0.31) | — | |
| SCHEMBL27026402 | 0.73 | NLRP3 (0.54) | NLRP3ACHENAMPTCYP2C9CYP2C19 | |
| SCHEMBL24978306 | 0.72 | ADORA2A (0.35) | CYP2C9CYP2C19CYP3A4 | |
| Hydrochloric Acid SCHEMBL28184544 | 0.71 | ACHE (0.45) | NLRP3ACHENAMPTCYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230031406-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230031406-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | NLRP3 2/4885ACHE 4177/4885NAMPT 92/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.